IL215372A0 - Methods and tools for predicting the efficiency of anthracyclines in cancer - Google Patents

Methods and tools for predicting the efficiency of anthracyclines in cancer

Info

Publication number
IL215372A0
IL215372A0 IL215372A IL21537211A IL215372A0 IL 215372 A0 IL215372 A0 IL 215372A0 IL 215372 A IL215372 A IL 215372A IL 21537211 A IL21537211 A IL 21537211A IL 215372 A0 IL215372 A0 IL 215372A0
Authority
IL
Israel
Prior art keywords
anthracyclines
predicting
cancer
tools
efficiency
Prior art date
Application number
IL215372A
Other languages
English (en)
Original Assignee
Univ Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bruxelles filed Critical Univ Bruxelles
Publication of IL215372A0 publication Critical patent/IL215372A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL215372A 2009-04-17 2011-09-25 Methods and tools for predicting the efficiency of anthracyclines in cancer IL215372A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2009/054606 WO2010118782A1 (fr) 2009-04-17 2009-04-17 Procédés et outils pour prédire l'efficacité d'anthracyclines dans le traitement du cancer
PCT/EP2010/055067 WO2010119133A1 (fr) 2009-04-17 2010-04-16 Procédés et outils pour prédire l'efficacité d'anthracyclines dans un cancer

Publications (1)

Publication Number Publication Date
IL215372A0 true IL215372A0 (en) 2011-12-29

Family

ID=41382440

Family Applications (1)

Application Number Title Priority Date Filing Date
IL215372A IL215372A0 (en) 2009-04-17 2011-09-25 Methods and tools for predicting the efficiency of anthracyclines in cancer

Country Status (5)

Country Link
JP (1) JP2012523828A (fr)
AU (1) AU2010238486A1 (fr)
CA (1) CA2758277A1 (fr)
IL (1) IL215372A0 (fr)
WO (2) WO2010118782A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY166040A (en) * 2010-09-15 2018-05-21 Almac Diagnostics Ltd Molecular diagnostic test for cancer
GB201018312D0 (en) * 2010-10-29 2010-12-15 Vib Vzw Metagene expression signature for prognosis of breast cancer patients
GB201306147D0 (en) * 2013-04-05 2013-05-22 Univ Ha Il Novel biomarker signature and uses thereof
WO2015169857A1 (fr) 2014-05-07 2015-11-12 Université Libre de Bruxelles Marqueurs épigénétiques du cancer du sein utiles pour le pronostic d'un traitement par l'anthracycline

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1441711A1 (fr) * 2001-11-09 2004-08-04 The University of Manitoba Traitement du cancer du sein
EP1365034A3 (fr) * 2002-05-21 2004-02-18 Bayer HealthCare AG Procédés et compositions pour la prédiction, le diagnostic, le pronostic, la prévention et le traitement de neoplasie maligne
JPWO2005007846A1 (ja) * 2003-04-25 2006-08-31 財団法人癌研究会 腫瘍細胞の抗癌剤に対する感受性を判定する方法
EP1631689A2 (fr) * 2003-05-28 2006-03-08 Genomic Health, Inc. Marqueurs de l'expression genetique permettant de predire la reponse une chimiotherapie
CA2531916A1 (fr) * 2003-07-10 2005-02-17 Central Institute For Experimental Animals Modele animal utile pour l'analyse des metastases tumorales
EP1769086A2 (fr) * 2004-07-18 2007-04-04 Epigenomics AG Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders
EP1782315A4 (fr) * 2004-07-30 2009-06-24 Rosetta Inpharmatics Llc Pronostic de patients atteints d'un cancer du sein
JP2008536094A (ja) * 2005-02-04 2008-09-04 ロゼッタ インファーマティクス エルエルシー 乳癌患者における化学療法反応性を予測する方法
JP2005323600A (ja) * 2005-06-06 2005-11-24 National Institute Of Advanced Industrial & Technology 遺伝子発現を指標にしたエストロゲン活性抑制効果評価法
AU2006326385B2 (en) * 2005-12-14 2012-10-04 James B. Hicks Use of ROMA for characterizing genomic rearrangements
CN101449162B (zh) * 2006-05-18 2013-07-31 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US20090280493A1 (en) * 2006-09-08 2009-11-12 Siemens Healthcare Diagnostics Inc. Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant Neoplasia
EP1961825A1 (fr) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Procédé pour prévoir l'apparition de métastase dans les patients souffrant d'un cancer du sein
WO2008155661A2 (fr) * 2007-04-16 2008-12-24 Ipsogen Procédés d'évaluation de l'aptitude d'un résultat clinique pour un mammifère femelle souffrant d'un cancer du sein
AU2008289148A1 (en) * 2007-08-16 2009-02-26 Aventis Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
AU2008294687A1 (en) * 2007-09-07 2009-03-12 Universite Libre De Bruxelles Methods and tools for prognosis of cancer in ER- patients

Also Published As

Publication number Publication date
AU2010238486A1 (en) 2011-11-03
JP2012523828A (ja) 2012-10-11
WO2010119133A1 (fr) 2010-10-21
CA2758277A1 (fr) 2010-10-21
WO2010118782A1 (fr) 2010-10-21

Similar Documents

Publication Publication Date Title
IL216708A0 (en) Corrosion-resistant cmp conditioning tools and methods for making and using same
ZA201204700B (en) Optimized endonucleases and uses thereof
EP2480744A4 (fr) Systèmes et procédés d'amélioration de rendement de forage
EP2433131A4 (fr) Particules et procédés pour sers à longueur d'onde longue
EP2497607A4 (fr) Outil motorisé
EP2470669A4 (fr) Procédés de sélection et d amplification de polynucléotides
EP2397277A4 (fr) Outil à entraînement par moteur
EP2520397A4 (fr) Outil motorisé
EP2106278A4 (fr) Extraction à ultrasons haute énergie
GB0823086D0 (en) Abrasive Tools
GB0823091D0 (en) Exfoliating vermiculite and other minerals
GB2473944B (en) Power tools
EP2481504A4 (fr) Insert de coupe et outil de coupe
EP2217117A4 (fr) Gril économe en énergie
IL215405A0 (en) O-ring inseryion tool and method
IL198407A0 (en) Cutting tool and cutting insert
EP2457092A4 (fr) Biomarqueur du cancer et son utilisation
SG10201405455UA (en) Cells and methods for obtaining them
IL196724A0 (en) Cutting insert and cutting tool
EP2300040A4 (fr) Procédés et compositions pour immunothérapie du cancer de la prostate
ZA201108848B (en) Improvements in efficiency
EP2475790A4 (fr) Procédés et compositions pour prédire une réponse à une thérapie anticancéreuse
EP2502691A4 (fr) Plaquette de coupe et outil de coupe
IL215372A0 (en) Methods and tools for predicting the efficiency of anthracyclines in cancer
GB0912744D0 (en) Methods and uses